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Abstract
Background: Locoregional recurrence is a major problem in esophageal cancer patients treated with definitive
concomitant chemoradiotherapy. Approximately half of the patients fail locoregionally. We analyzed the impact of
enlarged radiation field size and higher radiation dose incorporated to chemoradiotherapy on oncologic outcome.
Methods: Seventy-four consecutive patients with histologically proven nonmetastatic squamous or
adenocarcinoma of the esophagus were included in this retrospective analysis. All patients were locally advanced
cT3–T4 and/or cN0-1. Treatment consisted of either definitive concomitant chemoradiotherapy (Def-CRT) (n = 49,
66 %) or preoperative concomitant chemoradiotherapy (Pre-CRT) followed by surgical resection (n = 25, 34 %).
Patients were treated with longer radiation fields. Clinical target volume (CTV) was obtained by giving 8–10 cm
margins to the craniocaudal borders of gross tumor volume (GTV) instead of 4–5 cm globally accepted margins,
and some patients in Def-CRT group received radiation doses higher than 50 Gy.
Results: Isolated locoregional recurrences were observed in 9 out of 49 patients (18 %) in the Def-CRT group and
in 1 out of 25 patients (3.8 %) in the Pre-CRT group (p = 0.15). The 5-year survival rate was 59 % in the Def-CRT
group and 50 % in the Pre-CRT group (p = 0.72). Radiation dose was important in the Def-CRT group. Patients
treated with >50 Gy (11 out of 49 patients) had better survival with respect to patients treated with 50 Gy (38 out
of 49 patients). Five-year survivals were 91 and 50 %, respectively (p = 0.013).
Conclusions: Radiation treatment planning by enlarged radiation fields in esophageal cancer decreases
locoregional recurrences considerably with respect to the results reported in the literature by standard radiation
fields (18 vs >50 %). Radiation dose is as important as radiation field size; patients in the Def-CRT group treated
with ≥50 Gy had better survival in comparison to patients treated with 50 Gy.
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Background
Locoregional recurrence is a major concern and the pri-
mary mode of failure in esophageal cancer patients
treated either with surgery or definitive chemoradiother-
apy. The unique lymphatic network of the esophagus
and the absence of serosal covering around the organ
are the two major causes of high locoregional failures
after treatment [1–5].
Extensive, longitudinal interconnecting system of lym-
phatics facilitates not only early lympathic spread of the
tumors but also potential risk for lymphatic involvement
longitudinally throughout the entire length of the organ
rather than the segmental involvement of nodal areas [5].
Metastases to anatomically distant lymph nodes could de-
velop even in the early phases of lymphatic invasion and
up to 8 cm or more of normal tissue can exist between
the gross tumor and its micrometastases [5–10].
Lymph node metastases can be observed even with
superficial esophageal tumors. While the reported inci-
dence of nodal involvement is around 14 to 21 % for T1
tumors, this chiffre rises immediately up to 60 % for T2
tumors [5–10]. Autopsy findings demonstrate residual
or recurrent tumor in 60 % of the patients after curative
surgery. While local recurrences were observed in
25.6 % of autopsied cases, lymph node metastases were
observed in 41.9 % of the cases [11].
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Anatomic difficulty to remove the tumor and the
lymph nodes completely is suggested for high locoregio-
nal failures after surgical resection [11].
One striking and clinically unknown detail about the
involved lymph nodes in esophageal cancer is their
microscopic involvement in majority of the cases. Most
of the nodal involvement would not be radiologically or
clinically identifiable. The involved lymph nodes are
clinically evident in only 1/3rd of the cases [8–10].
Therefore, it is not appropriate to rely on varying im-
aging modalities to define areas of spread of the disease.
Spread pattern of lymph node metastases in defining tar-
get volumes will be more valuable in radiotherapy plan-
ning and field design.
Locoregional failures with curative intent surgery in
contemporary trials range from 32 to 45 % [2, 11–14].
Locoregional failures are also the major pattern of failure
in patients treated with definitive chemoradiotherapy
(Def-CRT), at least half of the patients fail locoregionally
[3, 4, 15]. Undetected persistent or recurrent subclinical
locoregional disease is very common in curatively
treated patients, and there are very high discordance
rates between clinic and pathologic stages in these pa-
tients [11, 16].
There is universal consensus in radiation therapy tar-
get volume delineation and radiation therapy target
doses in esophageal cancer treatment. The radiation field
design and dose of the Intergroup 0123 Trial became
the worldwide gold standard in definitive treatment and
recently, even in smaller radiation fields and lower radi-
ation doses in preoperative treatment of esophageal can-
cer [4, 15, 17–20]. In the Intergroup 0123 Trial, cranial
and caudal borders of the radiation fields were 5 cm be-
yond the gross tumor volume (GTV); the lateral, anter-
ior, and posterior borders of the fields were 2 cm beyond
the GTV. Although supraclavicular lymphatics were in-
cluded for tumors of the cervical esophagus, no special
attention was given to include the regional lymphatics
beyond 5 cm cranial and caudal borders of GTV in other
tumor locations [4].
The aim of this study is to analyze our patient experi-
ence with locally advanced esophageal carcinoma who
underwent either surgery following preoperative chemo-
radiotherapy (Pre-CRT) or Def-CRT using longer radi-
ation fields at craniocaudal borders of GTV and higher
radiation doses and the outcome of these treatment
parameters in terms of locoregional recurrence and
survival.
Methods
Seventy-four consecutive patients with histologically
proven non-metastatic squamous or adenocarcinoma of
the cervical, upper, middle, and lower third of the
esophagus were included in this retrospective study.
Three-hundred twenty esophageal cancer patients were
evaluated at the Dr. Lutfi Kirdar Kartal Education and
Research Hospital during this period. Two-hundred
forty-four patients were excluded from multimodality
treatment mainly due to patients undergoing straightfor-
ward surgery, exclusion secondary to patient-related factors
(prohibitive comorbidities for multimodality treatment) or
metastatic disease at presentation. All patients had clinical
T3–4, N0–1, and M0 tumors according to the sixth edi-
tion of American Joint Commission on Cancer staging
manual [21]. Tumor stage was evaluated by physical
examination, neck, thoracic, and abdominal computer-
ized tomography (CT), upper gastrointestinal endoscopy,
and, after 2008, by fluorodeoxyglucose positron emis-
sion tomography (PET-CT) (n = 27, 36 %). The patients
were analyzed in two groups. The first group comprised
patients seen first by a radiation oncologist and treated
with Def-CRT (n = 49, 66 %) with no planned esopha-
gectomy, and the second group comprised patients seen
first by a thoracic surgeon and referred for Pre-CRT
(n = 25, 34 %).
Patient and tumor characteristics are summarized in
Table 1. There were no differences between the two
groups with respect to patient and tumor characteristics.
Radiotherapy was administered using two-dimensional
(2D) planning technique (n = 30) and three-dimensional
(3D) conformal planning (n = 44) after 2007. Mega-
voltage photon energy ≥6 MV was used. While anterior
Table 1 Patient and tumor characteristics
Patient characteristics Pre-CRT (n= 25) Def-CRT (n= 49) P value
N (%) n (%)
Age, years
Median 53 ± 10.7 58.6 ± 12.1 0.055
Range 32–67 30–82
Gender (female/male) 17/8 28/21 0.37
Clinical T stage
3 13 29 0.56
4 12 20
Nodal stage
0 8 17 0.82
1 17 32
Histology
Adenocarcinoma 2 6 0.58
Squamous cell carcinoma 23 43
Esophageal location
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and posterior parallel opposed fields were used up to a
total dose of 46 Gy in 23 fractions with 2 Gy fractions
per day, 5 days per week in patients treated with 2D ra-
diation planning; anterior, posterior, and two lateral or
posterior oblique fields with same dose and fractionation
were used in patients treated with 3D radiation planning.
While radiation dose was 46 Gy in the Pre-CRT group
(n = 25), it was 50 Gy for middle and lower thoracic tu-
mors (n = 38) and between 50.1 and 60 Gy for upper
thoracic and cervical esophageal tumors (n = 11) in the
Def-CRT group.
The GTV was determined by computed tomography,
barium swallow, and endoscopy with or without PET-CT.
Initial clinical target volume (CTV1) was obtained by
expanding the GTV longitudinally at cranial and caudal
margins by 8–10 cm and transversal margins of 1.5–2 cm.
The planning target volume (PTV) contained the CTV1
and additional margins of 0.5 cm in all directions for con-
sideration of organ movements. After 46 Gy, boost was
planned for patients treated with Def-CRT. CTV2 for
boost was obtained by expanding GTV longitudinally by
4–5 cm and transversally by 1 cm. Two lateral fields were
used for patients treated with 2D planning (n = 20) and
one anterior (and or posterior) and or two lateral or pos-
terior oblique fields were used for patients treated with 3D
planning (n = 29).
Special attention has been given to keep the spinal
cord, heart, and lung radiation doses at tolerance levels,
and this has been achieved either by blocking for pa-
tients treated by 2D radiation planning or by multileaf
collimators treated by 3D radiation planning.
Chemotherapy was started on the same day as radio-
therapy. Several chemotherapy schemata either weekly,
three weekly, or monthly cycles were administered dur-
ing the study. The most common chemotherapy com-
bination used was cisplatin (CDDP) weekly either alone
(40 mg/m2) or together with other chemotherapeutic
agents (n = 56) and CDDP with infusional 5-fluorouracil
(5-FU) (n = 15) (CDDP, 75 mg/m2 on the first day of
weeks 1 and 5 of radiotherapy and 5-FU 1 g/m2 for the
first 4 days of weeks 1 and 5 of radiotherapy). Table 2
summarizes the treatment characteristics. Chemotherapy
was not continued after Def-CRT or Pre-CRT as adju-
vant treatment.
Twenty-five patients referred for Pre-CRT underwent
surgery by an experienced thoracic surgeon at a high
volume center. Surgery was performed at least 1 month
after the end of Pre-CRT. Transthoracic esophagectomy
with two-field lymphadenectomy was performed. Salvage
surgery was possible in 2 out of 9 patients treated with
Def-CRT after isolated locoregional recurrence.
The chemoradiation part of the treatment was performed
at Dr. Lutfi Kirdar Kartal Education and Research Hospital,
while the esophagectomies were performed at two centers.
Patients were seen 1 month after the end of treatment
and every 3 months up to 2 years, every 6 months up to
5 years, and yearly afterwards. Acute and late adverse re-
actions were evaluated according to the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (CTCAE), version 2.0. Late complications were
recorded for the lung, heart, and esophagus.
Recurrences were classified as locoregional only, dis-
tant only, and synchronous locoregional + distant. Locor-
egional recurrences (LR) were defined as recurrences at
the site of the primary tumor or locoregional lymph
nodes. Lymph node recurrences at the celiac trunk or in
the supraclavicular region were also considered to be
locoregional. Distant recurrences were defined as non-
regional lymph node recurrences and systemic metasta-
ses. Recurrences were detected by CT scan of the neck,
thorax, and abdomen and by endoscopy and/or by PET-
CT. LRs were analyzed in relation to the initial PTV and
were classified as in-field, when relapse was within PTV,
borderline when adjacent to PTV, or out-field when re-
lapse was outside PTV (Table 3).
The study was approved by local ethical committee of
Dr. Lutfi Kirdar Kartal Education and Research Hospital.
All patients gave informed consent.
Statistical analysis was performed using Fisher’s exact
and Student’s t test, chi-square test, Kaplan-Meier sur-
vival analysis, and log-rank test for comparisons using
IBM SPSS 20.0 software.
Results
Mean age of the whole cohort was 56.7 ± 11.9 (30–82,
45 females). Median and 5-year survivals were 91 months
and 56 %, respectively. Patient and tumor characteristics






n (%) n (%)
Radiation planning
Conventional (2D) 10 40 20 41 0.95
Conformal (3D) 15 60 29 59
Chemotherapy regimes
Cisplatin + infusional 5-FU 5 20 10 20 0.7
Weekly cisplatin 7 28 11 22
Weekly cisplatin + oral UFT 8 32 16 33
Weekly cisplatin + paclitaxel 3 12 7 14
Paclitaxel + 5-FU 1 4 2 5
Weekly cisplatin + capecitabine 1 4 3 6
Radiation dose (cGy)
4000–5000 25 100 39 78 0.01
5001–6000 0 0 11 22
CRT chemoradiotherapy, UFT oral uracil + tegafur
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which underwent both types of treatments are shown in
Table 1. The mean follow-up time was 60 months (range
1 to 156 months).
Overall median and 5-year survivals were 95 months
and 59 % in the Def-CRT group and 55 months and
50 % in the Pre-CRT group, respectively (p = 0.72, Fig. 1).
Cancer-specific 5-year survivals were 68 and 61 %, re-
spectively (p = 0.77). Cancer-specific median survivals
were not reached in both groups.
Locoregional recurrence rate was 18 % in the Def-CRT
group and 3.8 % in the Pre-CRT group. The difference be-
tween the groups was not statistically different (p = 0.15).
The decrease in locoregional recurrences reflected it-
self in both decreased distant metastases rates and in-
creased 5-year survival rates. Distant metastases were
observed in 5 out of 49 patients (10 %) in the Def-CRT
group and in 4 out of 25 patients (16 %) in the Pre-CRT
group (p = 0.25). All recurrences including locoregional,
distant, and synchronous locoregional + distant recur-
rences were observed in 18 out of 49 patients in the
Def-CRT group and in 8 out of 25 patients in the Pre-
CRT group, 37 vs 32 %, respectively (p = 0.69).
Recurrence patterns are summarized in Table 3 and
detailed in relation to the initial PTV.
Table 3 Tumor recurrences in relation to initial PTV
Recurrence Pre-CRT group (n = 25) Def-CRT group (n = 49) p value
Infield Outfield Borderline Infield Outfield Borderline
LRR only 0 0 1 7 1 1 0.15
Distant only 0 4 0 0 5 0 0.25
LRR plus distant 0 3 0 3 1 0 0.98
Total 8 18 0.69
LRR locoregional recurrence, CRT chemoradiotherapy
Fig. 1 Overall survival of groups who had preoperative chemoradiotherapy (Pre-CRT) or definitive chemoradiotherapy (Def-CRT). Overall median survivals
were 55 months (95 % CI 2–108) and 94.9 months and 5-year survival rates were 50 % (95 % CI 40–60) and 59 % (95 % CI 52–66), respectively (p= 0.72)
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Patients in the Def-CRT group received two different
radiation doses. The patients with cervical and upper
thoracic esophageal tumors (n = 11) were treated with
50.1–60 Gy, and the patients with middle and lower
thoracic esophageal tumors were treated with 50 Gy
(n = 38). While 5-year survival of the patients who were
treated with 50 Gy was 50 %, it was 91 % in patients
treated with doses between 50.1 and 60 Gy, and the differ-
ence was statistically significant (p = 0.013) (Fig. 2).
Postoperative morbidity was seen in six patients and
included pneumonia and anastomotic leakage. Postopera-
tive mortality was observed within 30 days in 2 patients
out of 25 (7 %) due to pneumonia and sepsis. Tumor spec-
imens were carefully analyzed for pathologic complete re-
sponse, and it was obtained in 8 out of 25 patients (31 %).
Common acute and late adverse events occurring during
Pre-CRT and Def-CRT are summarized in Table 4. Major
acute adverse events were related to myelosuppression and
esophagitis. Grade 3 or higher acute major toxicities were
observed in 57 % (n = 42) of patients, which necessitated
either dose reduction or termination of chemotherapy or a
break in the treatment. Grade 3 or higher late adverse
events were observed in 39 % (n = 29) of patients. There
were no acute adverse event-related deaths. While grade
3–4 acute adverse event rates in the Def-CRT and Pre-
CRT groups were similar (59 vs 52 %, p = 0.55), grade 3–4
late adverse event rates were more common in the Pre-
CRT group in comparison to the Def-CRT group (68 vs
24 %, p = 0.001). Among late adverse events, esophageal
strictures were the most common one and intervention
with dilatation was necessary in most of the patients of the
Pre-CRT group. This was related to the site of the anasto-
mosis which was left cervical area in operated patients.
Discussion
Def-CRT (cisplatin, 5-FU, and 50.4 Gy) became the
standard non-surgical treatment of patients with locore-
gionally advanced esophageal cancer after demonstration
of survival benefit in the Radiation Therapy Oncology
Group (RTOG) 85-01 Trial [3, 22]. However, locoregional
recurrence was very high (52 %) and it was the primary
mode of failure [3, 22]. The high locoregional failures
led to several subsequent trials with the aim of decreas-
ing locoregional recurrences, searching role of either in-
duction chemotherapy (5-FU, cisplatin, Intergroup 0122
Trial), or increasing radiation dose (5-FU, cisplatin, and
Fig. 2 Overall survival of patients who underwent definitive chemoradiotherapy (Def-CRT) with different radiotherapy doses. Overall median survival in
patients who received 50 Gy was 90 months (95 % CI 21–159). Median survival was not reached in patients who received >50 Gy. Five-year survival
rates were 50 % (95 % CI 42–58) and 91 % (95 % CI 82–100), respectively (p = 0.013)
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64.8 Gy, RTOG 94-05 Trial) [4, 23] or integration of
new generation chemotherapeutics, like paclitaxel
(RTOG 0113 Trial) [20]. None of those strategies re-
sulted in better locoregional control rates or survival.
On the contrary, these approaches resulted in increased
toxicity and treatment-related mortality [4, 20, 23]. The
radiation treatment parameters (radiation dose and field
design) of these new generation trials were the same as
that of the Intergroup 0123 Trial.
In our study, radiation treatment planning by length-
ening radiation field sizes at craniocaudal margins of
GTV decreased locoregional recurrences to 18 % in the
Def-CRT and to 3.8 % in the Pre-CRT group (Table 3).
This rate is very low when compared with the Inter-
group 0123 Trial (>50 %). The decrease in locoregional
recurrences translated in to decreased distant metastases
rates and increased 5-year survival rates, 59 % in defini-
tively treated and 50 % in preoperatively treated patients,
respectively. This is the result of effective coverage and
treatment of involved microscopic lymphatic and sub-
mucosal spread of the tumor, which was unidentifiable
with the current clinical staging.
Several authors tried to incorporate FDG-PET data to
improve the accuracy of tumor delineation in radiother-
apy planning [24–27]. However, even with the integra-
tion of PET data, accuracy of clinical staging is still far
away from pathologic staging; there are still problems to
support the use of FDG-PET in tumor delineation
process for radiation planning [24–27].
Muijs et al. evaluated pathologically the residual tumor
presence in relation to radiation therapy target volume
after Pre-CRT in 63 resectable esophageal cancer pa-
tients [28]. They demonstrated that macroscopically evi-
dent residual tumor within CTV and microscopic tumor
outside CTV were found in a substantial proportion of
the patients, 30 and 14 %, respectively. Residual tumor
outside the confines of CTV was found to be an adverse
prognostic factor for both locoregional recurrence and
survival [28].
Surgery decreases locoregional recurrences in locally
advanced esophageal cancer following chemoradiother-
apy by removing the residual tumor either in the lymph
nodes or in the primary tumor area (within CTV) rest-
ing viable due to insufficient radiation dose and also re-
moval of the residual tumor left outside the confines of
CTV due to insufficient radiation field size as demon-
strated by Muijs et al. [15, 17, 18, 28–36]. Decreased
locoregional recurrences in resectable patients following
Pre-CRT, on the other hand, result probably from
sterilization of tumor either in the lymph nodes or in
the primary tumor area which are not accessible to surgi-
cal resection due to proximity of the tumor to vital struc-
tures (circumferential resection margins) and anatomical
difficulty to remove the involved lymph nodes by surgery
and in turn increased R0 resection rates provided by de-
creased tumor bulk after Pre-CRT [15, 17, 18, 28–36]. In
both scenarios, surgery compensates for the insufficiency
of chemoradiotherapy in sterilizing tumor locoregionally.
Muijs et al. in their abovementioned trial demonstrated
two important findings. The first one was related to the
insufficiency of radiation dose utilized nowadays in Pre-
CRT, 41.4 Gy in 1.8 Gy fractions. This dose is preferen-
tially chosen so low in order to decrease the post chemo-
radiotherapy surgical complications [18, 28]. But 30 % of
the patients had macroscopically evident residual tumor
within CTV after 41.4 Gy [28]. Residual tumor within ra-
diation therapy target volume after Def-CRT with the
current standard radiation treatment parameters (50.4Gy,
Table 4 Acute and late adverse events due to treatment
Pre-CRT Def-CRT p value
G3 G4 G3 G4
Acute toxicity Esophagitis 3 2 10 3 0.66
Leukopenia 3 1 5 1 0.72
Neutropenia 3 1 3 – 0.21
Anemia 2 1 7 2 0.74
Thrombocytopenia 2 – 4 1 1
Nausea 4 – 3 – 0.21
Vomiting 1 – 6 – 0.41
Febrile neutropenia 1 – 2 – 1
Total events n = 8 n = 5 n = 24 n = 5 0.55
Late toxicity Cardiac 3 – 4 – 0.68
Pulmonary 4 – 2 – 0.17
Esophageal (stricture) 12 1 6 – <0.001
Total events n = 16 n = 1 n = 12 n = 0 <0.001
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5 cm margins to GTV) is also the most common cause of
locoregional failures [3, 4, 32, 33]. Residual tumor besides
causing locoregional failure also results in distant metasta-
ses and worsens prognosis [28, 32–35]. Residual tumor
outside CTV borders were identified in 14 % of the pa-
tients’ tumor pieces operated after Pre-CRT with a CTV
obtained by adding 3.5 cm margins to GTV craniocaudally
[28]. Pre-CRT with this field design and dose still im-
proved the results with respect to surgery alone and be-
came the new treatment standard in resectable esophageal
cancer (CROSS Trial) [17, 18]. Surgery provided R0 resec-
tion of residual gross tumor within CTV in 30 % of the
patients and residual tumor outside the CTV in 14 % of
the patients (approximately half of the patients) [28].
Thus, without surgery, almost half of these patients would
have failures demonstrating clearly the insufficiency of the
radiation treatment parameters (radiation dose and vol-
ume) [36]. But in two randomized trials comparing che-
moradiotherapy with or without surgery, the survival
difference did not reach statistical significance. However,
in these two randomized trials, the radiation doses of che-
moradiotherapy without surgery groups were higher than
those of the preoperative or standard chemoradiotherapy
alone trials [15, 37]. Increasing radiation dose of definitive
chemoradiotherapy treatment as in these two randomized
trials may decrease locoregional recurrences, and surgery
may not provide any additional benefit in these patients
when radiation doses are optimal.
Button et al. evaluated recurrences clinically by CT
and endoscopy in 145 patients in relation to radiation
therapy target volumes after Def-CRT with similar radi-
ation field design and dose as in the Intergroup 0123
Study [38]. They reported 49 % local failure rate as in
the Intergroup 0123 Trial. The authors considered the
radiation fields sufficient since most of the recurrences
are identified clinically within radiation therapy target
volumes [38]. They suggested that the radiation fields
used worldwide were acceptable and with larger radi-
ation fields, the results would not be better. However,
pathologic evaluation of recurrences in relation to radi-
ation therapy target volumes by Muijs et al. shed more
light on the relation between radiation field size and
locoregional recurrences. Muijs et al. demonstrated fur-
ther that residual tumor presence outside the borders of
CTV is associated with worse overall survival. However,
the authors instead of emphasizing the importance of in-
adequate CTV margins in radiation therapy target vol-
ume delineation consider the presence of residual tumor
cells outside CTV as an indicator of biologically more
aggressive tumor behavior [28, 36]. We think that re-
sidual tumor presence beyond the confines of CTV re-
sults from insufficient radiation field sizes rather than
aggressive tumor phenotype as opposed to author’s sug-
gestion [36]. Aggressive tumor phenotype may indirectly
result from accelerated repopulation of these untreated
residual tumor cells either outside or within CTV, which
in turn may confer resistance to eradication of the gross
tumor. These cells may constitute a focus for distant dis-
semination. The tumor cells left outside CTV, besides
being untreated by radiation part of the treatment, may
not be sterilized efficiently by the chemotherapy part of
the treatment. Muijs et al. demonstrated residual micro-
scopic tumor outside CTV in 14 % of the patients after
surgery which remained viable despite paclitaxel and
carboplatin combination chemotherapy administered
weekly throughout the radiation treatment [28]. One can
argue that chemotherapy administered during concomi-
tant treatment may not be as efficient as either induction
or adjuvant chemotherapy due to low dose intensity.
However, neither induction nor adjuvant chemotherapy
has shown to decrease the systemic dissemination in
esophageal cancer on contrary to common belief among
medical oncologists that early treatment and sterilization
of subclinical and micrometastatic disease is possible ei-
ther with induction or adjuvant chemotherapy [39–42].
The main contribution of chemotherapy in esophageal
cancer (less with induction, more with concomitant
approach) is the result of decrease in tumor bulk with
increased resectability and R0 resection rates by surgery
rather than sterilization of micrometastatic disease or
subclinical disease. In order for the chemotherapy to be
effective in patients with esophageal carcinoma both sys-
temically and locoregionally, it should be administered
concomitantly with radiotherapy ideally covering the
whole tumor cells within the esophagus [36, 42].
The radiation doses for preoperative or adjuvant treat-
ments in solid tumors are generally 46 to 50 Gy, and radi-
ation doses for definitive treatments are generally 60 Gy
or higher. However, higher radiation dose, 64.8 Gy, com-
pared with the standard radiation dose, 50.4 Gy, in defini-
tive treatment of locally advanced esophageal cancer in
the Intergroup 0123 Trial was not found to be beneficial
[4]. There were more treatment-related deaths with
64.8 Gy and similar locoregional recurrences in the two
arms of the trial, 56 vs 52 %. Failure of higher radiation
dose in the study is probably related to insufficiency of
radiation field size leaving residual tumor cells outside,
rather than the inefficiency of higher radiation dose.
Although there is evidence in the literature regarding the
importance of radiation dose escalation on locoregional
control rates in esophageal cancer, worldwide accepted
dose of definitive treatment is still 50.4 Gy, set as the ref-
erence dose as in target volumes after the Intergroup 0123
Trial [4, 43–46]. Radiation dose like longer radiation fields
was also found to be an important determinant of out-
come in the Def-CRT group of this retrospective study.
Patients treated with doses higher than 50 Gy (n = 11) had
better survival with respect to patients treated with 50 Gy
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(n = 38). Five-year survivals were 92 and 50 %, respectively
(p = 0.013).
There are several limitations of this study. It is retro-
spective and various chemotherapy regimens were used
over a decade. Our cohort was closely followed and has
an unusually high survival rate compared with other
contemporary series. This is most likely secondary to se-
lection bias. On the other hand, this strategy may well
lead to the elimination of subclinical disease which is
very frequent and clinically difficult to detect in esopha-
geal cancer. Our high locoregional control rates even in
the Def-CRT group may be related to the elimination of
satellite tumorlets and good coverage of subclinical
disease within CTV. Surgery can be questioned either in
resectable or in locally advanced patients in case the
patients are treated with optimal radiation treatment
parameters. It is very important to preserve organ while
treating efficiently the tumor in the esophagus. It may be
possible to achieve similar or better survivals with Def-
CRT both in resectable and locally advanced esophageal
cancer as in our study.
In conclusion, our results although retrospective are
encouraging. There is no major progress in treatment of
esophageal cancer since the Intergroup 0123 Trial in
unresectable disease and integration of Pre-CRT in re-
sectable disease. Radiation treatment parameters as used
in our study should be investigated in randomized trials
in order to ameliorate the results and decrease the ne-
cessity of surgery in this dismal disease with preservation
of organ and better quality of life.
Conclusions
Radiotherapy is an important treatment modality in
esophageal cancer, and it is the standard treatment ap-
proach in patients with locally advanced disease. How-
ever, radiation treatment parameters mainly radiation
field sizes and doses are not optimal and there is no
awareness of these points even among experts involved
in the treatment of this disease. Radiation treatment
with higher radiation dose and longer radiation fields
may improve the efficacy and success of this modality
in esophageal cancer management and decrease the
necessity of surgery. We demonstrated these assump-
tions in our study, and we think that our approach may
cure more patients with esophageal cancer.
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